Press Releases :: Sonnet BioTherapeutics, Inc. (PURR)

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

Feb 13, 2023 8:00am EST

Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update

Feb 08, 2023 8:00am EST

Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering

Feb 01, 2023 8:00am EST

Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

Jan 19, 2023 8:00am EST

Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010

Jan 09, 2023 8:00am EST

Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer

Dec 15, 2022 4:05pm EST

Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update

Nov 02, 2022 8:00am EDT

Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010

Nov 01, 2022 4:05pm EDT

Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022

Oct 31, 2022 7:30am EDT

Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates

Oct 04, 2022 8:00am EDT

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

1...
4
5
6
7
8
9
10
11
12
13